ProfileGDS5678 / 1452448_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 42% 43% 57% 41% 40% 40% 41% 41% 42% 41% 42% 41% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6347360
GSM967853U87-EV human glioblastoma xenograft - Control 22.963942
GSM967854U87-EV human glioblastoma xenograft - Control 33.009943
GSM967855U87-EV human glioblastoma xenograft - Control 43.4094257
GSM967856U87-EV human glioblastoma xenograft - Control 52.9061541
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0197640
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9834240
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9391641
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9341441
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9527742
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9473641
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9240642
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9607741
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9247940